-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Approximately 30% of pediatric patients with anaplastic large cell lymphoma (ALCL) will relapse
Lymphoma in children
From 2013 to 2017, the trial enrolled 68 children with ALK+ALCL, all of whom were treated with Bentuximab
Of the 67 children who could be assessed for toxicity, 66 had completed 6 courses of chemotherapy, for a total of 399 courses that could be assessed
EFS and OS
EFS and OSThe 2-year event-free survival rate (EFS) was 79.
The 2-year event-free survival rate (EFS) was 79.
EFS and OS of children with positive (+) or negative (-) NPM-ALK at baseline
EFS and OS of children with positive (+) or negative (-) NPM-ALK at baselineThe quantitative reverse transcription polymerase chain reaction of baseline NPM-ALK suggests that NPM-ALK has a certain predictive value for EFS (p=0.
The quantitative reverse transcription polymerase chain reaction of baseline NPM-ALK suggests that NPM-ALK has a certain predictive value for EFS (p=0.
Adding Bentuximab to standard chemotherapy does not increase the obvious toxicity or change the required treatment interval, and can prevent recurrence during treatment.
Original source:
Eric J.
Brentuximab vedotin in combination with chemotherapy for pediatric patients with ALK + ALCL: results of COG trial ANHL12P1
in this message
